Factors influencing receipt and time to treatment of immunotherapy relative to chemotherapy in stage III and stage IV melanoma

Ähnliche Einträge

• Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer
  von: Yong Liu, et al.
  Veröffentlicht: (2025)
• Initial chemotherapy dose reductions and subsequent treatment delivery in stage I–IIIA breast cancer
  von: Maria J. Monroy‐Iglesias, et al.
  Veröffentlicht: (2026)
• Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies
  von: Danai Dima, et al.
  Veröffentlicht: (2024)
• Subsequent surgical treatment or maintenance immunotherapy in stage III lung cancer patients achieving a favorable response following neoadjuvant immunotherapy: A matched retrospective cohort study from the surgical perspective
  von: Fuqiang Dai, et al.
  Veröffentlicht: (2024)
• Correction to “Omission of adjuvant chemotherapy in patients with completely necrotic Wilms tumor stage I and radiotherapy in stage III: The 30‐year SIOP‐RTSG experience.”
  Veröffentlicht: (2024)